Ozempic Takes A Back Seat As India Turns To Mounjaro For Weight Loss And Diabetes, How Much Does It Cost?

Add as a preferred source on Google

As India keeps pace with a rapidly growing global obesity crisis, one injectable medication is drawing significant attention. Mounjaro, developed by Eli Lilly, treats both type 2 diabetes and obesity, and since its India debut in March, the drug has made a remarkable impact.

Within three months, it amassed ₹24 crore in sales, with a staggering 60% month-over-month growth between April and May 2025. This sudden leap signals not just an early surge in demand, but a pivotal shift in how chronic diseases are managed in India.

Lightning-Fast Uptake Reflects Clear Demand

In May, Mounjaro sales reached ₹12.6 crore, up from ₹7.9 crore in April-a sharp 60% increase in just one month. Many analysts describe this as one of the fastest product adoptions by a pharmaceutical in India. Its early availability, months ahead of rivals like Ozempic and Wegovy, gave Eli Lilly a strategic advantage in a market seriously in need of weight-control therapies.

Photo Credit: Oneindia

Dosing Patterns Reveal Patient Preference

Market data indicates that the 5 mg dosage is now the fastest-growing segment. Its sales more than doubled from ₹3.08 crore to ₹7.53 crore between April and May, while the entry-level 2.5 mg dose rose to ₹5.08 crore. Physicians report a pattern: most patients start on 2.5 mg for four weeks, then shift to 5 mg to achieve stronger results. This gradual escalation model balances effectiveness with patient safety.

What's The Reason Behind Its Success

Mounjaro's active molecule, tirzepatide, targets two key metabolic receptors: GLP‑1 and GIP. This dual mechanism makes it more effective than single-receptor drugs like semaglutide (Ozempic), enhancing insulin release, reducing appetite, slowing digestion, and improving insulin sensitivity. Clinical trials have consistently shown tirzepatide yielding greater weight loss-and this real-world uptake echoes those findings.

Each pen of Mounjaro is priced transparently in India: ₹4,375 for 5 mg and ₹3,500 for 2.5 mg. At full dosage, patients spend around ₹14,000-17,500 per month, which positions it as a premium, yet accessible, therapeutic option. While pricier than many generics, its clear benefits and once-a-week dosage are contributing to its growing popularity among clinicians and patients alike.

Addressing India's Obesity And Diabetes Dual Burden

India is currently home to 180 million obese adults and 100 million people living with diabetes, the second highest rates globally. For doctors, Mounjaro fills a long-standing therapeutic gap. It's also increasingly used pre-bariatric surgery to reduce surgical risk. The emergence of such treatments aligns well with national health priorities targeting non-communicable diseases.

Photo Credit: Freepik

Although Ozempic (semaglutide) isn't yet available in India, its patent expires in January 2026, and leading pharma companies like Cipla, Dr Reddy's, Sun Pharma, and Biocon are already advancing generic GLP‑1 drugs. Biocon is even preparing its own versions of both semaglutide and tirzepatide. Once patents expire, cheaper generic options could drastically change the treatment landscape.

Mounjaro is making waves globally too. Eli Lilly reported $3.8 billion in global sales in the latest quarter-a year-over-year jump exceeding 55%. Wall Street analysts rate the company as "Outperform," with their outlook boosted by Mounjaro's performance . India's strong initial response reinforces wider beliefs in the drug's potential as a lucrative global healthcare innovation.

Despite its popularity, Mounjaro faces hurdles. Its cost remains out of reach for many, especially since health insurance rarely covers such medications in India . Concerns about off-label or "beauty-dosing" use, where people self-medicate for weight loss without proper oversight, highlight the need for stronger medical supervision. Experts warn such misuse could lead to side effects such as digestive issues, thyroid disruptions, or nutrient imbalances .

Disclaimer: The information provided in this article is for general informational and educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or a qualified healthcare provider with any questions you may have regarding a medical condition.